L&C BIO Co., Ltd.

As of March 31, 2026, L&C BIO Co., Ltd. carries a market capitalization of 1.60T, placing it among publicly traded companies globally. Its enterprise value stands at 1.65T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

L&C BIO Co., Ltd.'s next confirmed earnings release is scheduled for November 18, 2026.

As of March 31, 2026, L&C BIO Co., Ltd. has 24.61M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 15.96, and the price-to-book ratio stands at 7.90.

As of March 31, 2026, L&C BIO Co., Ltd. trades at an EV/EBITDA multiple of 86.81 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 16.83 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 155.72 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.65T versus a market cap of 1.60T, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, L&C BIO Co., Ltd. maintains a current ratio of 0.64, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, L&C BIO Co., Ltd. posted a negative return on equity (ROE) of -55.60, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -30.06, reflecting losses generated across the asset base. The company generates approximately 676.55M in revenue per employee across its workforce of 145.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.99 indicates how many times L&C BIO Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, L&C BIO Co., Ltd. recorded an income tax benefit of -21.16B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -156.40B and -135.14B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, L&C BIO Co., Ltd.'s stock has gained approximately 21.42% over the past 52 weeks. The 50-day moving average sits at 52,867.10, while the 200-day moving average is 66,362.15.

Over the twelve months ended March 31, 2026, L&C BIO Co., Ltd. generated 98.10B in revenue and converted that into -135.14B in net income, yielding earnings per share of -5,623.13. EBITDA reached 19.02B, while operating income came in at 10.60B.

As of March 31, 2026, L&C BIO Co., Ltd. holds 48.64B in cash and equivalents against 87.49B in total debt, resulting in a net debt position of 43.64B. Total book value stands at 202.84B, with working capital of -88.75B providing operational flexibility.

L&C BIO Co., Ltd. produced 19.40B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -22.99B in capital expenditures, free cash flow totaled -3.59B - equivalent to -149.32 per share.

Over the twelve months ended March 31, 2026, L&C BIO Co., Ltd. posted a gross margin of 55.03, reflecting its pricing power and cost economics. The operating margin of 10.81 and net profit margin of -137.76 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, L&C BIO Co., Ltd. paid dividends of 0.03 per share. The dividend payout ratio of 0.00 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -0.23: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.99, meaning L&C BIO Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

L&C BIO Co., Ltd.'s most recent stock split took place on September 3, 2026 with a 675:698 split ratio.

As of March 31, 2026, L&C BIO Co., Ltd. has an Altman Z-Score of 4.28, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.